XML 48 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Schedule of Error Corrections And Prior Period Adjustments (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2022
Aug. 01, 2022
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2023
Additional paid in capital     $ 29,996,963       $ 29,996,963   $ 29,489,055 $ 26,518,433 $ 12,063,940 $ 29,402,533 [1]
Accumulated deficit     (29,195,550)       (29,195,550)   (25,433,304) (18,840,581) (13,844,512) (23,792,804)
Research and development, net of contract expense reimbursements     645,719   $ 839,665   1,231,823 $ 1,761,466 3,517,093 1,047,385    
General and administrative     310,038   209,279   634,647 464,633 1,046,854 473,714    
Legal and professional     526,877   416,688   1,001,011 784,312 1,328,435 822,727    
Net loss from operations     (1,482,634)   (1,465,632)   (2,867,481) (3,010,411) (5,892,382) (2,343,826)    
Financing fee         (104,245) (104,245) (189,912)    
Change in fair value of derivative liabilities     (143,773)   434,275   54,089 1,675,275 2,216,488 (189,000)    
Change in fair value of warrant liabilities   $ (146,624)             (398,675)    
Loss on extinguishment of debt $ 1,531,852                 (1,795,652)    
Net loss                 (6,592,723) (4,996,069)    
Dividend on Series A Preferred Stock                 (402,064)    
Deemed dividend on extinguishment of Series A Preferred Stock                   (439,427)    
Deemed dividend on modification of equity-classified warrants, as restated                   (941,000)    
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                   31,423    
Net loss attributable to common stockholders     $ (2,031,215)   $ (2,184,372)   $ (3,762,246) $ (3,159,468) $ (6,592,723) $ (6,747,137)    
Net loss per shares - Basic     $ (0.96)   $ (1.23)   $ (1.80) $ (1.81) $ (3.53) $ (5.04)    
Net loss per shares - Diluted     $ (0.96)   $ (1.23)   $ (1.80) $ (1.81) $ (3.53) $ (5.04)    
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs $ 2,031,250                 $ 9,951,356 2,031,249  
Common stock issued for cash                      
Warrants exercised for cash                      
Warrants issued for financing costs           $ 90,816     $ 90,816 14,662    
Common stock issued for conversion of accrued interest                      
Common stock issued upon conversion of convertible debt and exercise of related warrants                   1,199,916    
Common stock issued for exercise of warrants with settlement of notes payable                   2,153,124    
Stock-based compensation     $ 71,162 $ 111,449 $ 49,522 8,333     181,960 237,547    
Dividends on Series A preferred stock                   (402,064)    
Common shares issued for dividends on and conversion of Series A preferred stock                   402,064    
Reclassification of fair value of warrant liability to equity upon initial public offering                 881,553    
Net loss     (2,031,215) $ (1,731,031) (2,184,372) (975,097) $ (3,762,246) $ (3,159,468) (6,592,723) (4,996,069)    
Change in fair value of derivative liabilities     143,773   (434,275)   (54,089) (1,675,275) (2,216,488) 189,000    
Change in fair value of warrant liabilities   $ 146,624             398,675    
Amortization of debt discount and finance fees             832,014 1,116,422 2,123,049 377,384    
Loss on settlement of convertible debt       $ 415,553   71,315 433,807 477,221 1,795,652    
Fair value of freestanding instruments in excess of proceeds                 189,912    
Gain on interest relief on conversion of notes payable                      
Stock-based compensation             182,611 57,855 181,960 237,547    
Accrued interest payable             20,445 75,511 110,453 18,378    
Net cash used in operating activities             (2,638,425) (2,984,039) (5,581,147) (2,666,411)    
Proceeds from issuance of common shares and warrants             9,995,513    
Proceeds from convertible notes payable             3,935,000 3,935,000 550,715    
Proceeds from notes payable and warrants                 50,000    
Payment for finance costs related to convertible notes payable                   (17,363)    
Net cash provided by (used in) financing activities             (501,667) 2,904,527 2,570,083 10,578,865    
Common stock issued upon conversion of convertible debt                   1,199,916    
Common stock issued for exercise of warrants with settlement of notes payable                 $ 2,153,124    
Common shares issued for dividends on and conversion of Series A preferred stock                 402,064    
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively             90,816 $ 90,816 $ 14,662    
Warranst of issuance fees           $ 8,727 $ 0 8,727 8,727 0    
Nonrelated Party [Member]                        
Interest expenses                   (428,688)    
Previously Reported [Member]                        
Additional paid in capital                 19,543,363 16,572,741 4,150,948 19,456,841 [1]
Accumulated deficit                 (15,487,612) (8,894,889) (5,795,432) (13,847,112)
Research and development, net of contract expense reimbursements               1,944,181   1,148,712    
General and administrative               281,918   538,796    
Legal and professional                   866,770    
Net loss from operations                   (2,554,278)    
Financing fee                      
Change in fair value of derivative liabilities                      
Change in fair value of warrant liabilities                   94,025    
Loss on extinguishment of debt                      
Net loss                   (3,028,448)    
Dividend on Series A Preferred Stock                   (71,009)    
Deemed dividend on extinguishment of Series A Preferred Stock                      
Deemed dividend on modification of equity-classified warrants, as restated                      
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                      
Net loss attributable to common stockholders                   $ (3,099,457)    
Net loss per shares - Basic                   $ (2.32)    
Net loss per shares - Diluted                   $ (2.32)    
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs                      
Common stock issued for cash                   10,008,095    
Warrants exercised for cash                   14,098    
Warrants issued for financing costs                   412,241    
Common stock issued for conversion of accrued interest                   588,524    
Common stock issued upon conversion of convertible debt and exercise of related warrants                      
Common stock issued for exercise of warrants with settlement of notes payable                   576,476    
Stock-based compensation                   403,956    
Dividends on Series A preferred stock                   (71,009)    
Common shares issued for dividends on and conversion of Series A preferred stock                   402,068    
Reclassification of fair value of warrant liability to equity upon initial public offering                      
Net loss                   (3,028,448)    
Change in fair value of derivative liabilities                      
Change in fair value of warrant liabilities                   (94,025)    
Amortization of debt discount and finance fees                   885,505    
Loss on settlement of convertible debt                      
Fair value of freestanding instruments in excess of proceeds                      
Gain on interest relief on conversion of notes payable                   12,625    
Stock-based compensation                   403,956    
Accrued interest payable                   (13,177)    
Net cash used in operating activities                   (2,710,454)    
Proceeds from issuance of common shares and warrants                   10,022,193    
Proceeds from convertible notes payable                   600,715    
Proceeds from notes payable and warrants                      
Payment for finance costs related to convertible notes payable                      
Net cash provided by (used in) financing activities                   10,622,908    
Common stock issued upon conversion of convertible debt                   588,524    
Common stock issued for exercise of warrants with settlement of notes payable                   $ 576,476    
Common shares issued for dividends on and conversion of Series A preferred stock                   402,068    
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively                   $ 412,241    
Previously Reported [Member] | Nonrelated Party [Member]                        
Interest expenses                   (917,879)    
Revision of Prior Period, Reclassification, Adjustment [Member]                        
Additional paid in capital                 9,945,692 9,945,692 [2] 7,912,992 [3] 9,945,692 [1]
Accumulated deficit                 $ (9,945,692) (9,945,692) [4] $ (8,049,080) [5] $ (9,945,692)
Research and development, net of contract expense reimbursements               (182,715)   (101,327)    
General and administrative               $ 182,715   (65,082)    
Legal and professional                   (44,043)    
Net loss from operations                   210,452    
Financing fee                   (189,912)    
Change in fair value of derivative liabilities                   (189,000)    
Change in fair value of warrant liabilities                   (492,700)    
Loss on extinguishment of debt                   (1,795,652)    
Net loss                   (1,967,621)    
Dividend on Series A Preferred Stock                   (331,055)    
Deemed dividend on extinguishment of Series A Preferred Stock                   (439,427)    
Deemed dividend on modification of equity-classified warrants, as restated                   (941,000)    
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                   31,423    
Net loss attributable to common stockholders                   $ (3,647,680)    
Net loss per shares - Basic                   $ (2.72)    
Net loss per shares - Diluted                   $ (2.72)    
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs                   $ 9,951,356    
Common stock issued for cash                   (10,008,095)    
Warrants exercised for cash                   (14,098)    
Warrants issued for financing costs                   (397,579)    
Common stock issued for conversion of accrued interest                   (588,524)    
Common stock issued upon conversion of convertible debt and exercise of related warrants                   1,199,916    
Common stock issued for exercise of warrants with settlement of notes payable                   1,576,648    
Stock-based compensation                   (166,409)    
Dividends on Series A preferred stock                   (331,055)    
Common shares issued for dividends on and conversion of Series A preferred stock                   (4)    
Reclassification of fair value of warrant liability to equity upon initial public offering                   881,553    
Net loss                   (1,967,621)    
Change in fair value of derivative liabilities                   189,000    
Change in fair value of warrant liabilities                   492,700    
Amortization of debt discount and finance fees                   (508,121)    
Loss on settlement of convertible debt                   1,795,652    
Fair value of freestanding instruments in excess of proceeds                   189,912    
Gain on interest relief on conversion of notes payable                   (12,625)    
Stock-based compensation                   (166,409)    
Accrued interest payable                   31,555    
Net cash used in operating activities                   44,043    
Proceeds from issuance of common shares and warrants                   (26,680)    
Proceeds from convertible notes payable                   (50,000)    
Proceeds from notes payable and warrants                   50,000    
Payment for finance costs related to convertible notes payable                   (17,363)    
Net cash provided by (used in) financing activities                   (44,043)    
Common stock issued upon conversion of convertible debt                   611,392    
Common stock issued for exercise of warrants with settlement of notes payable                   $ 1,576,648    
Common shares issued for dividends on and conversion of Series A preferred stock                   (4)    
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively                   $ (397,579)    
Revision of Prior Period, Reclassification, Adjustment [Member] | Nonrelated Party [Member]                        
Interest expenses                   $ 489,191    
[1] The Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated balance sheet for the period ended September 30, 2023 with an increase to additional paid in capital of $140 and an offsetting adjustment to the carrying value of common stock.
[2] Adjustments include corrections for stock compensation errors (increase of $7,843,052); recognition of Series A Preferred Stock accrued dividends (decrease of $402,064); correction of issuance cost recognition related to financing transactions (decrease of $174,082); corrections to the Company’s initial classification and recognition of warrants issued in financing transactions (decrease of $416,266), reclassifications of warrants from liability to equity (increase of $881,554); correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $2,213,498).
[3] Adjustments include adjustment to the carrying value of notes payable, including recognition of day 1 loss (decrease of $7,351); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); and stock compensation adjustments (increase of $8,009,461).
[4] Adjustments include corrections for stock compensation errors (increase of $8,009,461); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $240,930); reversal of accrued Series A Preferred Stock dividends (decrease of $402,064); recognition of bifurcated derivatives and recording of loss at issuance (increase of $296,151); correction of issuance cost recognition related to financing transactions (decrease of $166,407); and the aggregate adjustments to 2022 net loss as detailed below (increase of $1,967,621).
[5] Adjustments include reversal of dividend liability recorded (decrease of $331,059); identification of deferred IPO costs (decrease of ($55,182); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); adjustment to the estimated fair value of warrant liability (increase of $240,930); adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $274,048); and stock compensation adjustments (increase of $8,009,461).